Dr. Mithua Ghosh

Dr. Mithua Ghosh is a renowned cancer biologist and the founder of Lorven Biologics. With a strong background in cancer genomics and precision medicine, she has contributed significantly to the understanding of molecular mechanisms driving cancer progression. Her work bridges the gap between genomic research and its clinical applications, particularly in targeted therapies and diagnostics.

She is also actively involved in translational research and collaborations aimed at developing novel diagnostic tools for personalized cancer treatment. Through her leadership, she promotes access to affordable and advanced genomic solutions for cancer patients in India.

Qualification: PhD in Cancer Biology / Molecular Oncology
Specialty: Cancer Genomics & Molecular Diagnostics
Location: Bengaluru, Karnataka, India

Area of Expertise

Leadership in setting up comprehensive cancer genomics and liquid biopsy platform including next-generation sequencing, cytogenetics, and molecular diagnostics for targeted therapy decision-support.

Specialized in translational cancer biology research spanning oncogenes, p53 pathway signaling, and cancer stem cell biology in leukemia.

Proven track record in corporate R&D across biotech, academic, and pharmaceutical sectors, with contributions to biomarker advisory boards and ethics committees.

Medical Breakthrough

Developed and operationalized Triesta Genomics, HCG’s advanced genomics diagnostic unit that enables precision oncology across a cancer-treatment network.

Plays a key role in Institutional Ethics & Research advisory committees and national biomarker initiatives to support translational oncology research.

Awards & Accolades

Published numerous peer-reviewed articles on cancer stem cells, tumorigenesis mechanisms, and biomarker validation from postdoctoral work and corporate-industrial research.

Regular speaker and session chair at national and international conferences and workshops on oncology and genomics.

Dr. Mithua Ghosh

Dr. Mithua Ghosh

Dr. Mithua Ghosh

Area of Expertise

Leadership in setting up comprehensive cancer genomics and liquid biopsy platform including next-generation sequencing, cytogenetics, and molecular diagnostics for targeted therapy decision-support.

Specialized in translational cancer biology research spanning oncogenes, p53 pathway signaling, and cancer stem cell biology in leukemia.

Proven track record in corporate R&D across biotech, academic, and pharmaceutical sectors, with contributions to biomarker advisory boards and ethics committees.

Medical Breakthrough

Developed and operationalized Triesta Genomics, HCG’s advanced genomics diagnostic unit that enables precision oncology across a cancer-treatment network.

Plays a key role in Institutional Ethics & Research advisory committees and national biomarker initiatives to support translational oncology research.

Awards & Accolades

Published numerous peer-reviewed articles on cancer stem cells, tumorigenesis mechanisms, and biomarker validation from postdoctoral work and corporate-industrial research.

Regular speaker and session chair at national and international conferences and workshops on oncology and genomics.

Quick Links

Courses

Other Courses